Notice: This company has been marked as potentially delisted and may not be actively trading. Vermillion (VRML) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends VRML vs. VNRX, OCX, ICCC, CDIO, BMRA, TRIB, VRAX, AWH, TNFA, and MYMDShould you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include VolitionRx (VNRX), OncoCyte (OCX), ImmuCell (ICCC), Cardio Diagnostics (CDIO), Biomerica (BMRA), Trinity Biotech (TRIB), Virax Biolabs Group (VRAX), Aspira Women's Health (AWH), TNF Pharmaceuticals (TNFA), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "medical" sector. Vermillion vs. VolitionRx OncoCyte ImmuCell Cardio Diagnostics Biomerica Trinity Biotech Virax Biolabs Group Aspira Women's Health TNF Pharmaceuticals MyMD Pharmaceuticals Vermillion (NASDAQ:VRML) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment. Do analysts rate VRML or VNRX? VolitionRx has a consensus target price of $3.75, suggesting a potential upside of 562.54%. Given VolitionRx's stronger consensus rating and higher possible upside, analysts plainly believe VolitionRx is more favorable than Vermillion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vermillion 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has better valuation & earnings, VRML or VNRX? Vermillion has higher revenue and earnings than VolitionRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVermillion$4.54M3.75-$15.24MN/AN/AVolitionRx$1.29M40.79-$35.32M-$0.36-1.57 Does the media refer more to VRML or VNRX? In the previous week, VolitionRx had 3 more articles in the media than Vermillion. MarketBeat recorded 3 mentions for VolitionRx and 0 mentions for Vermillion. VolitionRx's average media sentiment score of 0.36 beat Vermillion's score of 0.00 indicating that VolitionRx is being referred to more favorably in the news media. Company Overall Sentiment Vermillion Neutral VolitionRx Neutral Which has more risk and volatility, VRML or VNRX? Vermillion has a beta of 3.47, suggesting that its share price is 247% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Does the MarketBeat Community believe in VRML or VNRX? Vermillion received 194 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 66.67% of users gave Vermillion an outperform vote while only 16.95% of users gave VolitionRx an outperform vote. CompanyUnderperformOutperformVermillionOutperform Votes20466.67% Underperform Votes10233.33% VolitionRxOutperform Votes1016.95%Underperform Votes4983.05% Is VRML or VNRX more profitable? Vermillion has a net margin of -307.31% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Vermillion's return on equity.Company Net Margins Return on Equity Return on Assets Vermillion-307.31% -155.25% -103.47% VolitionRx -2,321.14%N/A -163.39% Do insiders & institutionals believe in VRML or VNRX? 18.1% of Vermillion shares are held by institutional investors. Comparatively, 8.1% of VolitionRx shares are held by institutional investors. 4.4% of Vermillion shares are held by company insiders. Comparatively, 12.8% of VolitionRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryVermillion beats VolitionRx on 9 of the 17 factors compared between the two stocks. Remove Ads Get Vermillion News Delivered to You Automatically Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRML vs. The Competition Export to ExcelMetricVermillionDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.04M$2.48B$5.63B$8.08BDividend YieldN/A0.70%4.89%4.04%P/E Ratio-1.035.5623.8818.99Price / Sales3.7551.52381.87119.49Price / CashN/A15.7538.0534.64Price / Book1.943.086.904.26Net Income-$15.24M-$65.73M$3.19B$246.88M Vermillion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRMLVermillionN/A$0.18-12.5%N/A-94.6%$17.04M$4.54M-1.0343Gap UpHigh Trading VolumeVNRXVolitionRx1.313 of 5 stars$0.62-0.3%$3.75+506.8%-44.4%$57.27M$1.29M-1.7280Analyst ForecastNews CoverageGap DownOCXOncoCyte2.3512 of 5 stars$2.78-0.7%$4.42+58.9%+38.6%$48.52M$709,000.000.00120High Trading VolumeICCCImmuCell0.8832 of 5 stars$5.16-2.3%N/A-7.5%$45.99M$26.49M-10.3270Gap DownCDIOCardio Diagnostics3.1874 of 5 stars$0.42-6.3%$2.00+374.8%-71.3%$21.96M$35,688.000.001Short Interest ↓Positive NewsGap UpBMRABiomerica1.4222 of 5 stars$0.71-3.1%N/A-41.6%$13.06M$5.58M-2.0960Short Interest ↓Positive NewsGap UpTRIBTrinity Biotech1.5816 of 5 stars$0.70-4.8%N/A-66.1%$12.56M$59.13M-0.31480Short Interest ↓Gap UpVRAXVirax Biolabs Group0.7231 of 5 stars$1.59-4.8%N/A+70.1%$5.14M$84,872.000.005AWHAspira Women's Health1.1843 of 5 stars$0.17-0.4%$4.40+2,566.7%-95.3%$2.92M$8.96M-0.14110Short Interest ↑TNFATNF PharmaceuticalsN/A$0.39-6.0%N/AN/A$1.08MN/A0.006News CoverageHigh Trading VolumeMYMDMyMD PharmaceuticalsN/A$0.42-2.7%N/A-89.9%$991,000.00N/A0.006Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies VolitionRx Competitors OncoCyte Competitors ImmuCell Competitors Cardio Diagnostics Competitors Biomerica Competitors Trinity Biotech Competitors Virax Biolabs Group Competitors Aspira Women's Health Competitors TNF Pharmaceuticals Competitors MyMD Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRML) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vermillion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
